News & Updates · 7 August 2026 · 7 min read

Are Weight Loss Jabs Dangerous? The Truth About Deaths Linked to Wegovy and Mounjaro UK 2026

The MHRA has reported over 200 deaths suspected of being linked to weight loss injections. Before you panic, here's what those figures actually mean — and what the headlines are leaving out.

Last updated: April 2026 | 7 min read

If you've seen the headlines this week about deaths linked to weight loss injections, you're probably feeling worried. This article cuts through the scaremongering and gives you the honest, balanced picture — because the reality is more nuanced than the headlines suggest.

What the Headlines Are Actually Saying

The UK's medicines regulator, the MHRA, has published figures showing that more than 200 deaths have been reported as suspected of being linked to popular weight loss injections.

Specifically:

Those numbers sound alarming. But before you panic, here's what you absolutely need to understand.

The Most Important Thing to Know

The MHRA has stressed that these figures should not be interpreted as evidence that the medicines caused the deaths or illnesses.

This is crucial. The MHRA's reporting system — called the Yellow Card scheme — records any death that occurs in someone who was taking these medications. That does NOT mean the medication caused the death.

Think about it this way: if someone is taking Mounjaro and they die in a car accident, that death could technically be reported to the Yellow Card scheme. It doesn't mean Mounjaro caused the accident. Usage may have been entirely coincidental to a death, or an underlying illness completely unrelated to the drug may have played a role.

The Yellow Card scheme is a safety monitoring tool — it is designed to flag signals for further investigation, not to assign cause. Correlation is not causation.

How Many People Are Actually Taking These Medications?

This is the critical context the headlines leave out.

An estimated 1.6 million adults used weight loss drugs between early 2024 and early 2025 in the UK.

So we have 1.6 million people taking these medications — and 216 deaths reported as suspected links over the same period. That's a suspected association rate of around 0.013% — and remember, most of those deaths have not been proven to be caused by the medication at all.

To put that in perspective: obesity itself kills around 30,000 people per year in the UK. The medications designed to treat obesity carry a far smaller risk than the condition they treat.

What Is the MHRA Actually Investigating?

The main concern the MHRA is looking into is acute pancreatitis — inflammation of the pancreas.

The MHRA is investigating after 294 people suffered acute and chronic pancreatitis after taking tirzepatide and semaglutide. While none have been proven to be caused directly by the GLP-1 drugs, health officials have launched a new study into the harmful side effects.

Pancreatitis is a serious condition — but it's worth noting that obesity itself is a major risk factor for pancreatitis. Separating the effect of the medication from the underlying condition is genuinely complicated, and researchers are working to do exactly that.

Warning Signs to Watch For

The MHRA has asked anyone hospitalised with acute pancreatitis while taking a GLP-1 medication to report it via the Yellow Card scheme.

Seek urgent medical attention if you experience:

These could be signs of pancreatitis and need immediate medical assessment.

Also report to your prescriber if you notice:

None of these are common — but they are worth knowing about so you can act quickly if they occur.

Should You Stop Taking Your Medication?

No — not based on these headlines.

Neither the MHRA, the NHS, nor any major clinical body has recommended that people stop taking Wegovy, Mounjaro or Ozempic. The medications remain approved for use and continue to be prescribed across the UK.

If you have specific concerns about your health while taking a GLP-1 medication, the right thing to do is speak to your prescribing clinician — not stop suddenly. Stopping abruptly can lead to rapid weight regain and does not protect you from any risk associated with side effects you were already experiencing.

The Bottom Line

GLP-1 medications like Wegovy and Mounjaro are among the most thoroughly studied weight loss treatments ever approved. They have undergone years of large-scale clinical trials before reaching patients, and they continue to be monitored in real-world use.

The MHRA reporting these suspected links is the system working as intended — not evidence that these drugs are dangerous. It means regulators are watching carefully and will act if a genuine causal link is established.

The honest risk-benefit picture remains clearly in favour of treatment for people who are clinically obese. Obesity significantly increases the risk of type 2 diabetes, heart disease, stroke, certain cancers and early death. The evidence that GLP-1 medications reduce those risks — and improve lives — is substantial.

Stay informed. Stay in contact with your prescriber. And don't make clinical decisions based on newspaper headlines.

If you have concerns about your medication, contact your prescribing clinic or call NHS 111.

Where to Get Your GLP-1 Medication Safely in the UK

One of the best ways to protect yourself is to make sure you're getting your medication from a properly regulated UK clinic — not an unverified online seller. Regulated services include full medical assessments, ongoing monitoring, and direct access to clinicians if anything goes wrong.

Two services we recommend:

Voy — Clinically Led Weight Loss Programme

Voy is a fully regulated UK weight loss service offering Wegovy and Mounjaro prescriptions with ongoing clinical support. Every patient gets a personalised treatment plan, regular check-ins, and access to the clinical team throughout their journey.

Start Your Assessment at Voy →

SheMed — GLP-1 Clinic Built for Women

SheMed is a women-only weight loss clinic with a clinical team and care plan designed around female health. Particularly well regarded for women managing PCOS, perimenopause, or hormonal weight gain alongside GLP-1 treatment. From £59/month with a free blood test and unlimited clinician access included.

Check Eligibility at SheMed →

This article is for informational purposes only and does not constitute medical advice. GLP1Guide.live is not a medical service. Always consult a qualified healthcare professional before making any changes to your treatment. This article contains affiliate links — we may earn a small commission if you sign up through our links, at no extra cost to you.